Cargando…

Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma

Ipilimumab, a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody that potentiates antitumor T-cell responses, has demonstrated improved survival in previously treated and treatment-naïve patients with unresectable stage III/IV melanoma. Survival benefit has also been shown in dive...

Descripción completa

Detalles Bibliográficos
Autor principal: Chmielowski, Bartosz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665248/
https://www.ncbi.nlm.nih.gov/pubmed/23738073
http://dx.doi.org/10.1155/2013/423829
_version_ 1782271238369968128
author Chmielowski, Bartosz
author_facet Chmielowski, Bartosz
author_sort Chmielowski, Bartosz
collection PubMed
description Ipilimumab, a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody that potentiates antitumor T-cell responses, has demonstrated improved survival in previously treated and treatment-naïve patients with unresectable stage III/IV melanoma. Survival benefit has also been shown in diverse patient populations, including those with brain metastases. In 2011, ipilimumab (3 mg/kg every 3 weeks for 4 doses) was approved by the Food and Drug Administration for unresectable or metastatic melanoma. Ipilimumab can induce novel response patterns for which immune-related response criteria have been proposed. irAEs are common but are usually low grade; higher grades can be severe and life-threatening. irAEs are usually manageable using established guidelines emphasizing vigilance and prompt intervention. This agent provides an additional therapeutic option in metastatic melanoma, and guidelines for management of adverse events facilitate clinical implementation of this new agent.
format Online
Article
Text
id pubmed-3665248
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-36652482013-06-04 Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma Chmielowski, Bartosz J Skin Cancer Review Article Ipilimumab, a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody that potentiates antitumor T-cell responses, has demonstrated improved survival in previously treated and treatment-naïve patients with unresectable stage III/IV melanoma. Survival benefit has also been shown in diverse patient populations, including those with brain metastases. In 2011, ipilimumab (3 mg/kg every 3 weeks for 4 doses) was approved by the Food and Drug Administration for unresectable or metastatic melanoma. Ipilimumab can induce novel response patterns for which immune-related response criteria have been proposed. irAEs are common but are usually low grade; higher grades can be severe and life-threatening. irAEs are usually manageable using established guidelines emphasizing vigilance and prompt intervention. This agent provides an additional therapeutic option in metastatic melanoma, and guidelines for management of adverse events facilitate clinical implementation of this new agent. Hindawi Publishing Corporation 2013 2013-04-21 /pmc/articles/PMC3665248/ /pubmed/23738073 http://dx.doi.org/10.1155/2013/423829 Text en Copyright © 2013 Bartosz Chmielowski. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Chmielowski, Bartosz
Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma
title Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma
title_full Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma
title_fullStr Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma
title_full_unstemmed Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma
title_short Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma
title_sort ipilimumab: a first-in-class t-cell potentiator for metastatic melanoma
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665248/
https://www.ncbi.nlm.nih.gov/pubmed/23738073
http://dx.doi.org/10.1155/2013/423829
work_keys_str_mv AT chmielowskibartosz ipilimumabafirstinclasstcellpotentiatorformetastaticmelanoma